News Focus
News Focus
icon url

manibiotech

12/17/24 2:19 PM

#738241 RE: Galzus Research #738237

So then SA asked you to write the article ?
So they reached out to you , somehow singled you out to write it ?
Did they tell you if they were bearish or bullish ?
Did they tell you what the tone of the article needs to be ? 
icon url

dstock07734

12/17/24 2:22 PM

#738243 RE: Galzus Research #738237

You say "early-phase trials". As a Ph.D. in biochemistry, you really haven't impressed the longs with anything seminal or original. Did you say you wrote over 200 articles? How many of them were about an OTC? What's average life of a company that can stay on OTC? I assigned homework to a poster who wasted ten years of his life to take down this company. Have you ever read any papers about DC vaccine developed by other world-renowned scientists?

Here is the latest abstract from Dr. Liau. Here she only mentioned only three patients. Ask yourself why Dr. Liau considers it is enough based on the data from only three patients.

https://jitc.bmj.com/content/12/Suppl_2/A927

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
https://www.sciencedirect.com/science/article/pii/S0923753419345521

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
https://link.springer.com/article/10.1186/s13045-017-0459-2

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
https://aacrjournals.org/clincancerres/article/24/20/4937/258404/Therapeutic-Immune-Modulation-against-Solid

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
https://pmc.ncbi.nlm.nih.gov/articles/PMC8593702/